Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,024 active trials9 approved drugs78 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07532928 | A Bidirectional Study of Individualized Postoperative Adjuvant Treatment Decision Model for Locally Advanced Head and Neck Squamous Cell Carcinoma Based on Multimodal Dynamic Data | enrolling by invitation | — | 571 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07712328 | Randomized Controlled Clinical Study on the Prophylactic Intraoperative Use of Desmopressin in Complex Sellar Region Tumors(RCT-PIDST) | enrolling by invitation | Phase 4 | 152 | Zhaoyun Zhang |
| 1 |
| Jul 17, 2026 |
| clinicaltrials |
| NCT07218003 | A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 | enrolling by invitation | Phase 1 | 149 | Rondo TherapeuticsINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07618624 | BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression(BRIDGE) | enrolling by invitation | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07606638 | Effectiveness of Opioid vs Pregabalin Plus Naproxen Sodium in Pain Management of Oral Cancer Patients | enrolling by invitation | N/A | 98 | Mayo Hospital LahoreOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06885424 | A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products(DESCENT-1) | enrolling by invitation | — | 400 | A2 Biotherapeutics Inc.INDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT06782399 | Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma(SCC) | enrolling by invitation | Early Phase 1 | 25 | Oliver JonasOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07567716 | Infiltration Pattern of Locally Advanced ESCC | enrolling by invitation | — | 30 | Shanghai Chest HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07550972 | Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib. | enrolling by invitation | Phase 2 | 30 | Zhejiang Provincial People's HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03610906 | Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy | enrolling by invitation | — | 250 | University of Colorado, DenverOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07347392 | The Role of Radiotherapy for the Management of Non-melanoma Skin Cancer in Denmark.(DOSCA-2) | enrolling by invitation | — | 2,900 | University of AarhusOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07312578 | Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell Carcinoma | enrolling by invitation | Phase 2 | 48 | Peking UniversityOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07016737 | Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy(ESO-Nanjing12) | enrolling by invitation | Phase 3 | 79 | Ye jinjunOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT06690216 | Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors(PD-L1-PET) | enrolling by invitation | Phase 1 / Phase 2 | 100 | Man HuOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06715501 | Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma | enrolling by invitation | N/A | 20 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Mar 25, 2025 | clinicaltrials |
| NCT06863831 | A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC | enrolling by invitation | N/A | 536 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06647836 | The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma | enrolling by invitation | — | 1,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05376553 | Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck | enrolling by invitation | Phase 1 | 24 | Krzysztof MisiukiewiczOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06303583 | Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma(CRIS) | enrolling by invitation | Phase 1 / Phase 2 | 30 | Qiu GuoqinOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT03713229 | Seville Cohort of People Living With HIV at Risk for Anal Cancer(SeVIHanal) | enrolling by invitation | — | 3,000 | Hospitales Universitarios Virgen del RocíoOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06048926 | Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma | enrolling by invitation | N/A | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Jul 20, 2026source: clinicaltrials